Sida laga soo xigtay Jabbar et al. Jaamacadda Göteborg ee Iswiidhan, bartilmaameedka ballaaran ee ku saleysan saddexda biomarkers ee dareeraha cyst ayaa si sax ah u aqoonsan kara una qiimeyn kara suurtagalnimada Feejooyinka ganaca oo isu beddela kansarka ganaca . Waxaa habboon in la sameeyo daraasado kale si loo xaqiijiyo in habkan tijaabada ahi uu gacan ka geysan karo ogaanshaha kansarka waqtiga, si guul leh wax uga qabashada iyo ka hortagga kansarka. (J Clin Oncol. Nooca khadka tooska ah Noofambar 22, 2017)
Cystic lesions of the pancreas are very common in imaging, and about half are kansarka ganaca lesions. Therefore, accurate and specific diagnosis is essential for the correct treatment of patients. Unfortunately, the currently used diagnostic methods cannot effectively distinguish between pancreatic precancerous lesions and malignant pancreatic cystic lesions.
Cilmi baarayaashu waxay isticmaaleen shaybaarka dheecaanka cystic ee laga helay daloolinta iyadoo la raacayo hagitaanka endoscopy ultrasound-ka caadiga ah si loo falanqeeyo. Daraasad kooxeed oo ka kooban 24 bukaan ah, habka bayoolajiga borotiinka baaritaanka ayaa lagu aqoonsaday 8 musharax biomarkers oo bixin kara macluumaad ku saabsan isbeddelka halista ah iyo isbeddelada heerka sare ee 'dysplasia / cancer'. Ka dib, falanqaynta tirada ee 30 peptides lagu calaamadeeyay iyo isbarbar dhigga kormeerka muuqaalka guud ayaa lagu sameeyay bukaanada 80 ee xogta la diyaariyey iyo 68 bukaan ah oo ku jira set xaqiijinta. Darajada dhamaadka daraasadu waxay ahayd natiijada ogaanshaha cudurada wadnaha ama dabagalka caafimaad.
The results show that the best markers for malignant tumors may be a group of peptides derived from MUC-5AC and MUC-2. These markers can identify precancerous lesions / malignant lesions from benign lesions. The accuracy is as high as 97%. Compared with the cystic liquid carcinoembryonic antigen and cytological detection of these standard identification methods, the accuracy of these standard methods is 61% (95% CI 46% ~ 74%, P <0.001) and 84% (95% CI 71% ~ 92%, P = 0.02). MUC-5AC combined with prostate stem cell antigen can identify high-grade dysplasia or cancer, with an accuracy of 96%, can detect 95% of malignant lesions or severe dysplasia, and the detection rate of carcinoembryonic antigen and cytology 35% and 50% respectively (P <0.001, P = 0.003).
